Related Experiment Videos
Losartan for LIFE in hypertension with left ventricular hypertrophy?
1Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia. s.doggrell@mailbox.uq.edu.au
Insights
Losartan, an ACE inhibitor, demonstrated superior benefits over atenolol in reducing cardiovascular events and reversing left ventricular hypertrophy in hypertensive patients. This suggests losartan should be the standard treatment for hypertension when left ventricular hypertrophy is present.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Management
Background:
- Angiotensin-converting enzyme (ACE) inhibitors may not offer additional benefits over beta-blockers or calcium channel blockers when blood pressure reduction is equivalent.
- The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study investigated losartan versus atenolol in hypertensive patients with left ventricular hypertrophy (LVH).
Discussion:
- Despite similar blood pressure control, losartan showed greater benefits in the primary composite endpoint (cardiovascular mortality, stroke, myocardial infarction) compared to atenolol in hypertensive patients with LVH.
- Losartan also exhibited a superior capacity to reverse left ventricular hypertrophy (LVH) than atenolol.
- These findings suggest a potential advantage of ACE inhibitors, specifically losartan, in managing hypertension with concomitant LVH.
Key Insights:
- Losartan provides greater cardiovascular protection and LVH reversal than atenolol in hypertensive patients with LVH.
- The benefits extend to a subgroup of patients with both diabetes mellitus and LVH.
- This highlights the importance of considering LVH in hypertension treatment strategies.
Outlook:
- Losartan may represent a new standard of care for hypertension, particularly in patients with left ventricular hypertrophy.
- Further research could explore the long-term outcomes and cost-effectiveness of losartan in this patient population.
- Investigating the specific mechanisms behind losartan's superior LVH reversal could inform future therapeutic developments.
Abstract:
When ACE inhibitors are used to lower blood pressure to the same degree as beta-adrenoceptor antagonists or calcium channel blockers, ACE inhibitors do not seem to have additional benefits to these agents. In the Losartan Intervention for End Point Reduction in Hypertension study (LIFE), losartan was compared to atenolol in hypertensives with the additional risk factor of left ventricular hypertrophy (LVH). For similar effects on blood pressure, losartan had a greater benefit on the primary composite end point (cardiovascular mortality, stroke and myocardial infarction) than atenolol in the hypertensives with LVH, including a prespecified subgroup of patients with additional diabetes mellitus. Losartan also had a greater ability to reverse LVH than atenolol. Thus, losartan should become the standard treatment for hypertension when LVH is present.